<unk>  (DNS), also known as nalbuphine<unk>  or as sebacoyl<unk>  ester (SDE) and sold under the brand name Naldebain, is a non-controlled opioid analgesic which is used as a 7-day long-acting injection in the treatment of moderate to severe postoperative pain. The compound is a diester of nalbuphine (Nubain) joined via a sebacic acid linker, and acts as a long-lasting prodrug of nalbuphine via slow hydrolysis. It was developed to extend the duration of action of nalbuphine, which has a short duration and requires frequent injections. Whereas nalbuphine must be injected every 4 to 6 hours, a single injection of DNS lasts for up to 7 to 10 days. It was invented by professor Oliver Yoa-Pu Hu (National Defense Medical Center) and codeveloped with Lumosa Therapeutics. Naldebain received market approvals from Taiwan FDA in March 2017, Health Sciences Authority of Singapore in December 2020, and the Ministry of Public Health of Thailand in December 2021. Development is ongoing in the United States, China, Korea, Malaysia. Philippines, and Brunei.
Dinalbuphine sebacate
Drupanol
Benzyl benzoate
Melitracen
Modafinil sulfone
Entropion
Tavilermide
Olsalazine